Literature DB >> 27481954

Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.

John H Powers1, Kellee Howard2, Todd Saretsky2, Sarah Clifford2, Steve Hoffmann3, Lily Llorens4, George Talbot5.   

Abstract

The goal of administering medical interventions is to help patients live longer or live better. In keeping with this goal, there has been increasing interest in taking the "voice" of the patient into account during the development process, specifically in the evaluation of treatment benefits of medical interventions, and use of patient-centered outcome data to justify reimbursement. Patient-reported outcomes (PROs) are outcome assessments (OAs) used to define endpoints that can provide direct evidence of treatment benefit on how patients feel or function. When PROs are appropriately developed, they can increase the efficiency and clinical relevance of clinical trials. Several PROs have been developed for OA in specific infectious diseases indications, and more are under development. PROs also hold promise for use in evaluating adherence, adverse effects, satisfaction with care, and routine clinical practice.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  clinical practice; clinical trials; endpoints; infectious diseases; patient-reported outcomes

Mesh:

Substances:

Year:  2016        PMID: 27481954      PMCID: PMC5006216          DOI: 10.1093/cid/ciw317

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Patient non-compliance with paper diaries.

Authors:  Arthur A Stone; Saul Shiffman; Joseph E Schwartz; Joan E Broderick; Michael R Hufford
Journal:  BMJ       Date:  2002-05-18

2.  Sulphanilamide in Erysipelas.

Authors:  W R Snodgrass; T Anderson; J L Rennie
Journal:  Br Med J       Date:  1938-08-20

3.  Sulphanilamide in the Treatment of Erysipelas.

Authors:  W R Snodgrass; T Anderson
Journal:  Br Med J       Date:  1937-12-11

4.  Observers' errors in taking medical histories.

Authors:  A L COCHRANE; P J CHAPMAN; P D OLDHAM
Journal:  Lancet       Date:  1951-05-05       Impact factor: 79.321

5.  The effect of measuring error on the results of therapeutic trials in advanced cancer.

Authors:  C G Moertel; J A Hanley
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

Review 6.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Authors:  George H Talbot; John H Powers; Thomas R Fleming; Judith A Siuciak; John Bradley; Helen Boucher
Journal:  Clin Infect Dis       Date:  2012-06-28       Impact factor: 9.079

Review 7.  Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Authors:  Thomas R Fleming; John H Powers
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

Review 8.  Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods.

Authors:  Alan Shields; Cheryl Coon; Yanni Hao; Meaghan Krohe; Andrew Yaworsky; Iyar Mazar; Catherine Foley; Denise Globe
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-11-23       Impact factor: 2.217

9.  Global rating of change scales: a review of strengths and weaknesses and considerations for design.

Authors:  Steven J Kamper; Christopher G Maher; Grant Mackay
Journal:  J Man Manip Ther       Date:  2009

10.  Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.

Authors:  Zobair M Younossi; Maria Stepanova; Fatema Nader; Linda Henry
Journal:  J Am Geriatr Soc       Date:  2016-01-30       Impact factor: 5.562

View more
  16 in total

1.  Assessing Noninferiority in Treatment Trials for Severe Infectious Diseases: an Extension to the Entire Follow-Up Period Using a Cure-Death Multistate Model.

Authors:  Harriet Sommer; Tobias Bluhmki; Jan Beyersmann; Martin Schumacher
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors.

Authors:  Marco Colizzi; Maddalena Peghin; Maria De Martino; Giulia Bontempo; Valentina Gerussi; Alvisa Palese; Miriam Isola; Carlo Tascini; Matteo Balestrieri
Journal:  Rev Psiquiatr Salud Ment       Date:  2022-06-17       Impact factor: 6.795

3.  Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

Authors:  George H Talbot; Anita Das; Stephanie Cush; Aaron Dane; Michele Wible; Roger Echols; Antoni Torres; Sue Cammarata; John H Rex; John H Powers; Thomas Fleming; Jeffrey Loutit; Steve Hoffmann
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

Review 4.  Patient-reported outcomes in vaccines research: relevance for decision-making.

Authors:  Desmond Curran; Eliazar Sabater Cabrera; Linda Nelsen
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

5.  Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Authors:  Thomas P Lodise; Sam Colman; Elizabeth Alexander; Daniel S Stein; David Fitts; Lisa Goldberg; Jennifer Schranz
Journal:  Open Forum Infect Dis       Date:  2020-06-03       Impact factor: 3.835

6.  The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.

Authors:  Joseph P Menetski; Steven C Hoffmann; Stephanie S Cush; Tania Nayak Kamphaus; Christopher P Austin; Paul L Herrling; John A Wagner
Journal:  Clin Pharmacol Ther       Date:  2019-04       Impact factor: 6.875

7.  Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine.

Authors:  Maher R Khdour; Heba B Awadallah; Dua'a H Al-Hamed
Journal:  J Diabetes Res       Date:  2020-08-25       Impact factor: 4.011

8.  Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.

Authors:  Rita Daubner-Bendes; Sándor Kovács; Maciej Niewada; Mirjana Huic; Michael Drummond; Oriana Ciani; Carl Rudolf Blankart; Olena Mandrik; Aleksandra Torbica; John Yfantopoulos; Guenka Petrova; Malwina Holownia-Voloskova; Rod S Taylor; Maiwenn Al; Oresta Piniazhko; László Lorenzovici; Rosanna Tarricone; Antal Zemplényi; Zoltán Kaló
Journal:  Front Public Health       Date:  2021-01-08

9.  Patient-reported outcomes in breast cancer FDA drug labels and review documents.

Authors:  Kyungwan Hong; Kayleigh R Majercak; Ester Villalonga-Olives; Eleanor M Perfetto
Journal:  J Patient Rep Outcomes       Date:  2021-04-21

10.  Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.

Authors:  Maddalena Peghin; Alvisa Palese; Margherita Venturini; Maria De Martino; Valentina Gerussi; Elena Graziano; Giulia Bontempo; Francesco Marrella; Alberto Tommasini; Martina Fabris; Francesco Curcio; Miriam Isola; Carlo Tascini
Journal:  Clin Microbiol Infect       Date:  2021-06-07       Impact factor: 13.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.